Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLG | P54098 | 5/20 | 0.40 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.33 |
| ▸ | TKT | P29401 | 1/20 | 0.32 |
| ▸ | PNP | P00491 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | POLA1 | P09884 | 1/20 | 0.30 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.30 |
| ▸ | EP300 | Q09472 | 1/20 | 0.30 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.30 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.30 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.30 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.30 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.30 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.30 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27997587 | 0.86 | EP300 (0.32) | EP300 | |
| SCHEMBL27581641 | 0.79 | EP300 (0.32) | EP300 | |
| SCHEMBL10496372 | 0.75 | POLG (0.47) | POLGP2RY2PNPPOLBP2RY6 | |
| SCHEMBL76047 | 0.75 | POLG (0.47) | POLGP2RY2PNPPOLBP2RY6 | |
| SCHEMBL26123976 | 0.74 | POLG (0.47) | POLGP2RY2PNPPOLBP2RY6 | |
| SCHEMBL27824403 | 0.72 | EP300 (0.33) | EP300 | |
| SCHEMBL1452492 | 0.72 | POLB (0.44) | POLBPOLA1 | |
| SCHEMBL3364511 | 0.72 | POLB (0.44) | POLBPOLA1 | |
| SCHEMBL1144357 | 0.71 | POLG (0.44) | POLGP2RY2PNPPOLBPOLA1 | |
| SCHEMBL446614 | 0.71 | POLA1 (0.35) | P2RY2POLBPOLA1ENPP1P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115335390-A | Vaccines and compositions based on the S protein of SARS-CoV-2 | 广州市锐博生物科技有限公司 | 2022-11-11 | — | — | CN | claimed |
| CN-114213509-B | S protein vaccine based on SARS-CoV-2 and its use | 广州市锐博生物科技有限公司 | 2022-06-10 | — | — | CN | claimed |
| CN-114031675-B | Vaccines and compositions based on the S protein of SARS-CoV-2 | 广州市锐博生物科技有限公司 | 2022-06-07 | — | — | CN | claimed |
| CN-114423870-A | Cell-free production of ribonucleic acids | 绿光生物科学公司 | 2022-04-29 | — | — | CN | claimed |
| CN-112480217-B | Vaccines and compositions based on S antigen protein of SARS-CoV-2 | 广州阿格纳生物医药制造有限公司 | 2022-04-08 | — | — | CN | claimed |
| CN-114213509-A | S protein vaccine based on SARS-CoV-2 and its use | 广州市锐博生物科技有限公司 | 2022-03-22 | — | — | CN | claimed |
| CN-114031675-A | Vaccines and compositions based on the S protein of SARS-CoV-2 | 广州市锐博生物科技有限公司 | 2022-02-11 | — | — | CN | claimed |
| CN-113925975-A | preparation method of p53 and UTX messenger RNA nanoparticles and application of messenger RNA | 杭州师范大学 | 2022-01-14 | — | — | CN | claimed |
| CN-112480217-A | Vaccines and compositions based on S antigen protein of SARS-CoV-2 | 广州市锐博生物科技有限公司 | 2021-03-12 | — | — | CN | claimed |
| US-20020197642-A1 | Primer-mediated polynucleotide synthesis and manipulation techniques | STRATAGENE | 2002-12-26 | — | — | US | claimed |
| US-20010031483-A1 | Primer-mediated polynucleotide synthesis and manipulation techniques | STRATAGENE | 2001-10-18 | — | — | US | claimed |
| WO-1997028282-A1 | IMPROVED PRIMER-MEDIATED POLYNUCLEOTIDE SYNTHESIS AND MANIPULATION TECHNIQUES | STRATAGENE (US) | 1997-08-07 | — | — | WO | claimed |
| CN-115960926-A | mRNA and mRNA-containing medicine | 南方科技大学 | 2023-04-14 | — | — | CN | disclosed |
| CN-115960180-A | 2019-nCoV S protein mutant and genetically engineered mRNA and vaccine composition thereof | 北京启辰生生物科技有限公司 | 2023-04-14 | — | — | CN | disclosed |
| CN-109803977-B | Nucleic acid products and methods of administration thereof | 菲克特生物科学股份有限公司 | 2023-03-17 | — | — | CN | disclosed |
| CN-115335390-A | Vaccines and compositions based on the S protein of SARS-CoV-2 | 广州市锐博生物科技有限公司 | 2022-11-11 | — | — | CN | disclosed |
| US-6261797-B1 | SYNTHESIZING TARGET POLYNUCLEOTIDES USING PRIMERS WHICH HAVE RECOGNITION SITES FOR A RELEASING ENZYME JOINED TO A REGION FOR ANNEALING TO THE TARGET POLYNUCLEOTIDE TEMPLATE; THE FINAL AMPLIFIED PRODUCT IS RELEASED FROM THE SOLID SUPPORT | STRATAGENE | 2001-07-17 | — | — | US | disclosed |
| US-5962228-A | DNA SEQUENCING USING PRIMER WALKING; REPEATED CYCLES OF NUCLEOTIDE IDENTIFICATION BY SELECTIVE EXTENSION AND PRIMER ADVANCEMENT ALONG TEMPLATE BY TEMPLATE MUTATION; PRIMERS HAVE COMPLEXITY-REDUCING NUCLEOTIDES | LYNX THERAPEUTICS, INC. (US) | 1999-10-05 | — | — | US | disclosed |
| US-5780231-A | DNA SEQUENCING | LYNX THERAPEUTICS, INC. (US) | 1998-07-14 | — | — | US | disclosed |
| WO-1997028282-A1 | IMPROVED PRIMER-MEDIATED POLYNUCLEOTIDE SYNTHESIS AND MANIPULATION TECHNIQUES | STRATAGENE (US) | 1997-08-07 | — | — | WO | disclosed |